Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer

Conditions

• Recurrent Small Cell Lung Carcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Laboratory Biomarker Analysis — OTHER
  Correlative studies
• Pegylated Irinotecan — DRUG
  Given IV
• Pharmacological Study — OTHER
  Correlative studies

Study Details

This phase II trial studies how well pegylated irinotecan NKTR 102 works in treating patients with small cell lung cancer that has returned after a period of improvement. Pegylated irinotecan NKTR 102 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date

Aug 29, 2013

Status verified

Mar 2020

Primary completion

Jul 18, 2017

Completion

Feb 24, 2020

Study Design

Enrollment

38 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (pegylated irinotecan NKTR 102)
  Patients receive pegylated irinotecan NKTR 102 IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity

Primary Outcome Measure

18 Week Progression-free Survival Rate [ Time Frame: Time from registration to the date of first documented disease progression or death, assessed at 18 weeks ]

Locations (3)

Find similar trials in Buffalo, NY